Ποια είναι η τιμή για Galmed Pharmaceuticals Ltd. (GLMD)

Η τιμή για Galmed Pharmaceuticals Ltd. (GLMD) είναι $0.5225

Ποια είναι η κεφαλαιοποίηση αγοράς για Galmed Pharmaceuticals Ltd. (GLMD)

Η κεφαλαιοποίηση αγοράς για Galmed Pharmaceuticals Ltd. (GLMD) είναι $4.32M

Galmed Pharmaceuticals Ltd. (GLMD) Τιμή και Κεφαλαιοποίηση Αγοράς

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Η τιμή για GLMD	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$659,772 $4.32M	NVDA	$5.452T	+126,272,059.88%
$543,372 $4.32M	AAPL	$4.490T	+103,994,452.40%
$503,725 $4.32M	GOOG	$4.162T	+96,406,517.01%
$444,902 $4.32M	MSFT	$3.676T	+85,148,645.89%
$342,848 $4.32M	AMZN	$2.833T	+65,616,754.42%

Η τιμή για GLMD

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$659,772 $4.32M